GLPG vs. JANX, VERA, SDGR, PTCT, MRVI, RNA, AMPH, SNDX, DYN, and GPCR
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Janux Therapeutics (JANX), Vera Therapeutics (VERA), Schrödinger (SDGR), PTC Therapeutics (PTCT), Maravai LifeSciences (MRVI), Avidity Biosciences (RNA), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), Dyne Therapeutics (DYN), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.
In the previous week, Janux Therapeutics had 10 more articles in the media than Galapagos. MarketBeat recorded 13 mentions for Janux Therapeutics and 3 mentions for Galapagos. Janux Therapeutics' average media sentiment score of 0.52 beat Galapagos' score of -0.50 indicating that Janux Therapeutics is being referred to more favorably in the news media.
Galapagos has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.
Galapagos has a net margin of -26.25% compared to Janux Therapeutics' net margin of -721.18%. Galapagos' return on equity of -2.60% beat Janux Therapeutics' return on equity.
Galapagos has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 4.18, meaning that its stock price is 318% more volatile than the S&P 500.
Galapagos currently has a consensus price target of $34.50, suggesting a potential upside of 19.34%. Janux Therapeutics has a consensus price target of $61.33, suggesting a potential upside of 25.55%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Galapagos.
32.5% of Galapagos shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 35.4% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Galapagos received 446 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 64.63% of users gave Galapagos an outperform vote while only 58.82% of users gave Janux Therapeutics an outperform vote.
Summary
Janux Therapeutics beats Galapagos on 10 of the 18 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
